摘要
[目的]探讨补肺活血汤治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。[方法]选择2016年1月-2017年12月收治的103例COPD稳定期患者,根据随机数字表法分为对照组和治疗组,其中对照组51例、治疗组52例。对照组患者给予常规治疗措施,治疗组患者在对照组治疗的基础上给予补肺活血汤治疗,两组均连续给予治疗12周。评价并比较两组临床疗效。评价两组治疗前后的中医证候评分、6 min步行距离和生活质量评分。测定两组治疗前后的第1秒用力呼气量(FEV1)、用力肺活量(FVC)及FEV1和FVC的比值(FEV1/FVC)。检测两组治疗前后血清白介素-8(IL-8)、α1-抗胰蛋白酶(α1-AT)水平。记录治疗过程中严重不良反应的发生情况。[结果]治疗组的总有效率(88.46%)高于对照组(70.59%,P<0.05)。治疗后,两组FEV1、FVC及FEV1/FVC均较同组治疗前增大(P<0.05),且治疗组FEV1、FVC及FEV1/FVC变化均优于对照组(P<0.05)。治疗后,两组血清IL-8水平均较同组治疗前降低(P<0.05)、血清α1-AT水平均较同组治疗前升高(P<0.05),且治疗组血清IL-8、α1-AT水平变化均优于对照组(P<0.05)。治疗后,两组6 min步行距离均较同组治疗前增大(P<0.05),中医证候积分和生活质量评分均较同组治疗前减小(P<0.05),且治疗组中医证候积分、6 min步行距离及生活质量评分变化均优于对照组(P<0.05)。两组治疗过程中均无严重的不良反应发生。[结论]补肺活血汤治疗稳定期COPD的临床疗效显著,能够明显改善患者的肺功能,提高运动能力和生活质量,推测其作用机制可能与抑制气道炎症反应有关,且安全性较好,值得在临床上推广应用。
[Objective] To explore the clinical efficacy of Bufei Huoxue Decoction in the treatment of stable chronic obstructive pulmonary disease(COPD).[Methods] A total of 103 patients with stable COPD from January 2016 to December 2017 were enrolled in this study. According to the random number table method,the subjects were divided into the control group(n=51) and the treatment group(n=52). The patients in the control group were given routine treatment. The patients in the treatment group were treated with Bufei Huoxue Decoction on the basis of the treatment in the control group,and the two groups were treated continuously for 12 weeks. The clinical efficacy of the two groups after treatment was evaluated and compared. The score of TCM syndromes,6-minute walking distance and quality of life was evaluated before and after treatment. The first second forced expiratory volume(FEV1),forced vital capacity(FVC) and the ratio of FEV1 to FVC(FEV1/FVC) was measured before and after treatment. Serum level of interleukin-8(IL-8) and α1-antitrypsin(α1-AT) was measured before and after treatment in both groups. The occurrence of serious adverse reactions during the treatment of the two groups was recorded.[Results] The total effective rate of the treatment group(88.46%) was higher than that of the control group(70.59%,P<0.05). After treatment,FEV1,FVC and FEV1/FVC in the two groups increased significantly compared with those in the same group before treatment(P<0.05),and the changes of FEV1,FVC and FEV1/FVC in the treatment group was better than those in the control group(P<0.05). After treatment,the level of serum IL-8 in both groups was lower than those before treatment in the same group(P<0.05),and serum α1-AT level was higher than those before treatment in the same group(P<0.05),and the change of serum IL-8 and α1-AT levels in the treatment group was better than those in the control group(P<0.05). There were no serious adverse reactions in both groups.[Conclusion] Bufei Huoxue Decoction is effective in treating stable COPD. It can improve lung function,exercise ability and quality of life. It is speculated that the mechanism of Bufei Huoxue Decoction may be related to inhibiting airway inflammation,and its safety is good. It is worth popularizing and applying in clinic.
作者
刘亚茹
刘玉静
纪品川
LIU Yaru;LIU Yujing;JI Pinchuan(First Department of Internal Medicine,Chengde Traditional Chinese Medicine Hospital,Chengde 067000,China;Department ofGeratology,Chengde Traditional Chinese Medicine Hospital,Chengde 067000,China)
出处
《天津中医药》
CAS
2019年第7期650-654,共5页
Tianjin Journal of Traditional Chinese Medicine
基金
承德市科学技术研究与发展计划资助项目(20151088)
